Prolonged remissions in adults with acute leukemia following rate intensification chemotherapy and immunotherapy

G. P. Bodey, E. J. Freireich, K. B. McCredie, T. L. Smith, Evan M Hersh, J. U. Gutterman, E. M. Hersh

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Sixty-two patients with acute leukemia who remained in continuous complete remission for 8 to 45 months received three courses of intensified therapy with new chemotherapeutic agents, after which they received no further chemotherapy. Immunotherapy with BCG was then administered to 55 of these patients. They have been observed for up to 117 months off all chemotherapy, and 37 patients have relapsed. Thirty-two relapses occurred within 24 months, and 22 occurred within 6 months after completion of late intensification therapy. Only 1 of 24 patients who remained in unmaintained remission for 4 years after late intensification therapy has relapsed subsequently. Toxicity from intensification therapy was usually mild, and the most serious side effects were liver function abnormalities. These results suggest that late intensification therapy plus BCG immunotherapy results in prolonged disease-free survival for some patients with acute leukemia.

Original languageEnglish (US)
Pages (from-to)1937-1945
Number of pages9
JournalCancer
Volume47
Issue number8
DOIs
StatePublished - 1981
Externally publishedYes

Fingerprint

Immunotherapy
Leukemia
Drug Therapy
Mycobacterium bovis
Therapeutics
Disease-Free Survival
Recurrence
Liver

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prolonged remissions in adults with acute leukemia following rate intensification chemotherapy and immunotherapy. / Bodey, G. P.; Freireich, E. J.; McCredie, K. B.; Smith, T. L.; Hersh, Evan M; Gutterman, J. U.; Hersh, E. M.

In: Cancer, Vol. 47, No. 8, 1981, p. 1937-1945.

Research output: Contribution to journalArticle

Bodey, G. P. ; Freireich, E. J. ; McCredie, K. B. ; Smith, T. L. ; Hersh, Evan M ; Gutterman, J. U. ; Hersh, E. M. / Prolonged remissions in adults with acute leukemia following rate intensification chemotherapy and immunotherapy. In: Cancer. 1981 ; Vol. 47, No. 8. pp. 1937-1945.
@article{68fb28d217f748deba7736543ade4d03,
title = "Prolonged remissions in adults with acute leukemia following rate intensification chemotherapy and immunotherapy",
abstract = "Sixty-two patients with acute leukemia who remained in continuous complete remission for 8 to 45 months received three courses of intensified therapy with new chemotherapeutic agents, after which they received no further chemotherapy. Immunotherapy with BCG was then administered to 55 of these patients. They have been observed for up to 117 months off all chemotherapy, and 37 patients have relapsed. Thirty-two relapses occurred within 24 months, and 22 occurred within 6 months after completion of late intensification therapy. Only 1 of 24 patients who remained in unmaintained remission for 4 years after late intensification therapy has relapsed subsequently. Toxicity from intensification therapy was usually mild, and the most serious side effects were liver function abnormalities. These results suggest that late intensification therapy plus BCG immunotherapy results in prolonged disease-free survival for some patients with acute leukemia.",
author = "Bodey, {G. P.} and Freireich, {E. J.} and McCredie, {K. B.} and Smith, {T. L.} and Hersh, {Evan M} and Gutterman, {J. U.} and Hersh, {E. M.}",
year = "1981",
doi = "10.1002/1097-0142(19810415)47:8<1937::AID-CNCR2820470804>3.0.CO;2-G",
language = "English (US)",
volume = "47",
pages = "1937--1945",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Prolonged remissions in adults with acute leukemia following rate intensification chemotherapy and immunotherapy

AU - Bodey, G. P.

AU - Freireich, E. J.

AU - McCredie, K. B.

AU - Smith, T. L.

AU - Hersh, Evan M

AU - Gutterman, J. U.

AU - Hersh, E. M.

PY - 1981

Y1 - 1981

N2 - Sixty-two patients with acute leukemia who remained in continuous complete remission for 8 to 45 months received three courses of intensified therapy with new chemotherapeutic agents, after which they received no further chemotherapy. Immunotherapy with BCG was then administered to 55 of these patients. They have been observed for up to 117 months off all chemotherapy, and 37 patients have relapsed. Thirty-two relapses occurred within 24 months, and 22 occurred within 6 months after completion of late intensification therapy. Only 1 of 24 patients who remained in unmaintained remission for 4 years after late intensification therapy has relapsed subsequently. Toxicity from intensification therapy was usually mild, and the most serious side effects were liver function abnormalities. These results suggest that late intensification therapy plus BCG immunotherapy results in prolonged disease-free survival for some patients with acute leukemia.

AB - Sixty-two patients with acute leukemia who remained in continuous complete remission for 8 to 45 months received three courses of intensified therapy with new chemotherapeutic agents, after which they received no further chemotherapy. Immunotherapy with BCG was then administered to 55 of these patients. They have been observed for up to 117 months off all chemotherapy, and 37 patients have relapsed. Thirty-two relapses occurred within 24 months, and 22 occurred within 6 months after completion of late intensification therapy. Only 1 of 24 patients who remained in unmaintained remission for 4 years after late intensification therapy has relapsed subsequently. Toxicity from intensification therapy was usually mild, and the most serious side effects were liver function abnormalities. These results suggest that late intensification therapy plus BCG immunotherapy results in prolonged disease-free survival for some patients with acute leukemia.

UR - http://www.scopus.com/inward/record.url?scp=0019460308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019460308&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19810415)47:8<1937::AID-CNCR2820470804>3.0.CO;2-G

DO - 10.1002/1097-0142(19810415)47:8<1937::AID-CNCR2820470804>3.0.CO;2-G

M3 - Article

C2 - 6939480

AN - SCOPUS:0019460308

VL - 47

SP - 1937

EP - 1945

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8

ER -